Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Socioeconomic Determinants and the Biology and Outcomes of Acute Lymphoblastic Leukemia in Adults

Blood (2023) 142 (Supplement 1): 1468.

https://doi.org/10.1182/blood-2023-174963

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

David A. Rizzieri, MD, Jeffrey L Johnson, John C. Byrd, MD, Gerard Lozanski, MD, Bayard L. Powell, MD, Thomas C. Shea, MD, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, MD, Richard Larson, M.D.

Blood (2010) 116 (21): 858.

https://doi.org/10.1182/blood.V116.21.858.858

Published: 2010

Journal Articles

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Xiaopan Yao, PhD, MS, Elisabeth Paietta, PhD, Rhett Ketterling, Witold Rybka, MD, Mark R. Litzow, MD, Jacob M. Rowe, Richard Larson, M.D., Martin S. Tallman, MD

Blood (2010) 116 (21): 3315.

https://doi.org/10.1182/blood.V116.21.3315.3315

Published: 2010

Journal Articles

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Eyal C Attar, M.D., Kathleen A. Donohue, M.A., Philip C. Amrein, MD, Martha Wadleigh, MD, Daniel J DeAngelo, MD, PhD, Jonathan E Kolitz, MD, Bayard L. Powell, MD, Peter M Voorhees, M.D., Eunice S. Wang, MD, William Blum, MD, Allison Booth, Richard M Stone, M.D., Barry K Moser, Ph.D., Richard Larson, M.D.

Blood (2010) 116 (21): 331.

https://doi.org/10.1182/blood.V116.21.331.331

Published: 2010

Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 58.

https://doi.org/10.1182/blood.V116.21.58.58

Published: 2010

Journal Articles

High frequency of PTEN, PI3K , and AKT abnormalities in T-cell acute lymphoblastic leukemia

Alejandro Gutierrez, Takaomi Sanda, Ruta Grebliunaite, Arkaitz Carracedo, Leonardo Salmena, Yebin Ahn, Suzanne Dahlberg, Donna Neuberg, Lisa A. Moreau, Stuart S. Winter, Richard Larson, Jianhua Zhang, Alexei Protopopov, Lynda Chin, Pier Paolo Pandolfi, Lewis B. Silverman, Stephen P. Hunger, Stephen E. Sallan, A. Thomas Look

Blood (2009) 114 (3): 647–650.

https://doi.org/10.1182/blood-2009-02-206722

Published: 2009

Includes: Supplemental data

Journal Articles

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Zejuan Li, MD, PhD, Jun Lu, PhD, Miao Sun, MS, Shuangli Mi, PhD, Hao Zhang, MS, Roger T. Luo, PhD, Zhijian Qian, PhD, Mary Beth Neilly, MS, Yungui Wang, PhD, Jie Jin, MD, Yanming Zhang, MD, Stefan K. Bohlander, MD, Richard Larson, MD, Michelle LeBeau, PhD, Michael J. Thirman, MD, Todd R. Golub, MD, Janet D. Rowley, MD, Jianjun Chen, PhD

Blood (2007) 110 (11): 3181.

https://doi.org/10.1182/blood.V110.11.3181.3181

Published: 2007

Journal Articles

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Pamela Becker, Adam Boruchov, David Bowen, Richard Larson, Roger Lyons, Petra Muus, Jamile Shammo, Michael Ehrman, Kuolung Hu, Janet Nichol

Blood (2007) 110 (11): 250.

https://doi.org/10.1182/blood.V110.11.250.250

Published: 2007

Journal Articles

MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia.

Shuangli Mi, PhD, Jun Lu, Ph.D., Miao Sun, M.S., Zejuan Li, Ph.D., Hao Zhang, M.S., Mary Beth Neilly, M.S., Yungui Wang, Ph.D., Zhijian Qian, Ph.D., Jie Jin, M.D., Yanming Zhang, M.D., Stefan K. Bohlander, M.D., Michelle M. Le, B.A., Richard Larson, M.D., Todd R. Golub, M.D., Janet D. Rowley, M.D., Jianjun Chen, Ph.D.

Blood (2007) 110 (11): 231.

https://doi.org/10.1182/blood.V110.11.231.231

Published: 2007

Journal Articles

Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).

Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Peter Paschka, MD, Guido Marcucci, MD, Andreas Anhalt, Katja Urlbauer, Jürgen Krauter, MD, Richard Larson, MD, Krzysztof Mrózek, MD, Amy S. Ruppert, MD, Arnold Ganser, MD, Michael A. Caligiuri, MD, Hartmut Döhner, MD, Richard F. Schlenk, MD, Clara D. Bloomfield, MD, Konstanze Döhner, MD

Blood (2007) 110 (11): 762.

https://doi.org/10.1182/blood.V110.11.762.762

Published: 2007

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).

Oliver Ottmann, MD, Hagop Kantarjian, MD, Richard Larson, MD, Philipp le Courte, MD, Michele Baccarani, MD, Teresa Rafferty, Aaron Weitzman, MD, Francis Giles, MD

Blood (2006) 108 (11): 1862.

https://doi.org/10.1182/blood.V108.11.1862.1862

Published: 2006

Journal Articles

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Christopher Daugherty, MD, Lucy Godley, MD PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD PhD, Sonali M. Smith, MD, Todd Zimmerman, MD, Yanming Zhang, PhD, Dezheng Huo, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2006) 108 (11): 3675.

https://doi.org/10.1182/blood.V108.11.3675.3675

Published: 2006

Journal Articles

A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).

Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard Larson, Teresa Rafferty, Aaron Weitzman, Ariful Haque, Francis Giles, S.G. O’Brien, Philipp le Coutre

Blood (2006) 108 (11): 2169.

https://doi.org/10.1182/blood.V108.11.2169.2169

Published: 2006

Journal Articles

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, François Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, Rudiger Hehlmann

Blood (2006) 108 (6): 1809–1820.

https://doi.org/10.1182/blood-2006-02-005686

Published: 2006

Journal Articles

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Lucy Godley, MD, PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD, PhD, Sonali M. Smith, MD, Richard Larson, MD, Koen Van Besien, MD

Blood (2005) 106 (11): 2022.

https://doi.org/10.1182/blood.V106.11.2022.2022

Published: 2005

Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD

Blood (2005) 106 (11): 2520.

https://doi.org/10.1182/blood.V106.11.2520.2520

Published: 2005

Journal Articles

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Francois Guilhot, MD, Lydia Roy, MD, Joelle Guilhot, BS, Tillmann Krahnke, BSR, Agnes Guerci, MD, Brian Druker, MD, Richard Larson, MD, Steve O’Brien, MD, Charlene So, PharmD, Giorgio Massimini, MD

Blood (2005) 106 (11): 165.

https://doi.org/10.1182/blood.V106.11.165.165

Published: 2005

Journal Articles

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Koen W. van Besien, MD, Andrew Artz, MD, Sonali Smith, MD, Elizabeth Rich, MD, Lucy Godley, MD, PhD, Demetria Jones, Paula Del Cerro, RN, Diane Switzer, RN, Brendan Casey, Olatoyosi Odenike, MD, Michael Thirman, MD, Chris Daugherty, MD, Todd M. Zimmerman, MD, Richard Larson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 2321.

https://doi.org/10.1182/blood.V104.11.2321.2321

Published: 2004

Journal Articles

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, MS, Wendy Stock, MD, Sonali M. Smith, MD, Christopher Daugherty, MD, Lucy Godley, MD, PhD, Todd Zimmerman, MD, Olatoyosi M. Odenike, MD, Michael Thirman, MD, Elizabeth Rich, MD, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2004) 104 (11): 1145.

https://doi.org/10.1182/blood.V104.11.1145.1145

Published: 2004

NARROW

Socioeconomic Determinants and the Biology and Outcomes of Acute Lymphoblastic Leukemia in Adults

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

High frequency of PTEN, PI3K , and AKT abnormalities in T-cell acute lymphoblastic leukemia

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia.

Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only